JP Patent

JP7822477B2 — Ｒｅｔ阻害剤であるセルペルカチニブの結晶形態ａの調製方法

Assigned to Loxo Oncology Inc · Expires 2026-03-02 · 0y expired

What this patent protects

Patent listed against Retevmo.

Drugs covered by this patent

Retevmo (SELPERCATINIB) · Eli Lilly

Patent Metadata

Patent number: JP7822477B2
Jurisdiction: JP
Classification: —
Expires: 2026-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Loxo Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.